Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 4/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240772 | 0.81 | TSHR (0.58) | TSHRLMNALOXL2ALDH1A1CYP2C19 | |
| SCHEMBL11567222 | 0.81 | LOXL2 (0.55) | TSHRLMNALOXL2ALDH1A1CYP2C19 | |
| SCHEMBL1176909 | 0.80 | TSHR (0.56) | TSHRLMNALOXL2ALDH1A1CYP2C19 | |
| SCHEMBL334475 | 0.80 | TSHR (0.56) | TSHRLMNALOXL2ALDH1A1CYP2C19 | |
| SCHEMBL8186292 | 0.80 | TSHR (0.56) | TSHRLMNALOXL2ALDH1A1CYP2C19 | |
| Hydrochloric Acid SCHEMBL4360113 | 0.79 | TSHR (0.55) | TSHRLMNALOXL2ALDH1A1CYP2C19 | |
| SCHEMBL9969480 | 0.79 | TSHR (0.55) | TSHRLMNALOXL2ALDH1A1CYP2C19 | |
| SCHEMBL19938068 | 0.79 | TSHR (0.55) | TSHRLMNALOXL2ALDH1A1CYP2C19 | |
| SCHEMBL18118460 | 0.79 | TSHR (0.55) | TSHRLMNALOXL2ALDH1A1CYP2C19 | |
| SCHEMBL14541037 | 0.77 | MEN1 (0.49) | TSHRLMNALOXL2ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637410-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-11999676-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2023245156-A2 | VESICULAR MONOAMINE TRANSPORTER-2 LIGANDS AND THEIR USE IN THE TREATMENT OF PSYCHOSTIMULANT ABUSE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20220315523-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-10-06 | — | — | US | disclosed |
| US-20200290948-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290948-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | SLC18A2, SLC6A2, SLC6A3 | TSHR 928/4885LMNA 3785/4885LOXL2 2356/4885 |
| US-12637410-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | SLC18A2, SLC6A2, SLC6A3 | TSHR 758/4885LMNA 2694/4885LOXL2 2395/4885 |
| US-11999676-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | SLC18A2, SLC6A2, SLC6A3 | TSHR 928/4885LMNA 3785/4885LOXL2 2356/4885 |
| US-20220315523-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | SLC18A2, SLC6A2, SLC6A3 | TSHR 963/4885LMNA 3941/4885LOXL2 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.